SHOX CNE9/10 Knockout in U2OS Osteosarcoma Cells and Its Effects on Cell Growth and Apoptosis.

CONCLUSIONS Knockdown of CNE9 and CNE10 promoted U2OS cell growth and inhibited apoptosis by decreasing SHOX expression. This CNE9/CNE10 knockout U2OS cell model could provide a bridge for the research on SHOX and CNEs in osteosarcoma. PMID: 32032347 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research

Related Links:

AbstractOsteosarcoma (OS) is a kind of primary bone cancer that is considered as the leading cause of children death. Surgery and chemotherapy are considered as common treatment approaches for OS; the rate of survival for patients is almost 60 –70%. Besides the used therapeutic approaches, it seems that there is a crucial need to launch new treatments for OS. In this regard, more understanding about cellular and molecular pathways involved in OS can contribute to recovery and develop new therapeutic platforms. Autophagy is a cellular ma chinery that digests and degrades dysfunctional proteins and organelles, so it ca...
Source: IUBMB Life - Category: Research Authors: Tags: CRITICAL REVIEW Source Type: research
CONCLUSIONS: The addition of mifamurtide to chemotherapy might improve event-free survival by decreasing the probability of distant metastasis in bad histologic responders, and also by increasing the time to distant metastasis in the surgical margin positive group. Additional clinical studies are necessary to determine the long-term effects of mifamurtide on metastatic disease.. PMID: 32212798 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Condition:   Osteosarcoma Interventions:   Drug: Ganoderma lucidum;   Drug: Chemotherapy;   Drug: Placebos Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we aimed to explore the functions of PTBP1 in chemoresistance of osteosarcoma. We found that PTBP1 was significantly increased in chemotherapeutically insensitive osteosarcoma tissues and cisplatin-resistant osteosarcoma cell lines (MG-63CISR and U-2OSCISR ) as compared to chemotherapy-sensitive osteosarcoma tissues and cell lines. Knock-down of PTBP1 can enhance the anti-proliferation and apoptosis-induced effects of cisplatin in MG-63CISR and U-2OSCISR cells. Moreover, PTBP1 knock-down significantly up-regulated the expression of the copper transporter SLC31A1, as indicated by transcriptome sequencing. Thr...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
Condition:   Osteosarcoma Interventions:   Drug: neoadjuvant chemotherapy+SPIONs/SMF;   Drug: neoadjuvant chemotherapy Sponsors:   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Leiden University Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biomedical Science | Bone Cancers | Cancer & Oncology | Chemotherapy | Genetics | Osteosarcoma | Research | Science | Study